Clinical outcome in patients with rheumatoid arthritis switched to tumor nesrosis factor blockers after tocilizumab or abatacept

Clinical outcome in patients with rheumatoid arthritis switched to tumor nesrosis factor blockers after tocilizumab or abatacept - Clinical outcome in patients with RA switched to TNF blocker after tocilizumab or abatacept

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016950

Enrollment

Registered

2015-04-03

Start date

2015-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Infliximab or adalimumab or golimumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: active rheumatoid arthritis patients (disease activity score-ESR >2.6) after 1st BIO (tocilizumab or abatacept) failure

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Clinical remission rate in 48w (DAS28ESR<2.6)	—

Secondary

Measure	Time frame
Power Dopper signal	—

Countries

Japan

Contacts

Public ContactShuzo Yoshida

Osaka Medical College Department of Internal Medicine (I)

in1307@osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026